What is AbbVie's indefinite- lived intangible impairment?

AbbVie (ABBV) reported indefinite- lived intangible impairment of $94.8B in Q1 2026.

How has AbbVie's indefinite- lived intangible impairment changed year-over-year?

AbbVie's indefinite- lived intangible impairment decreased by 0.5% year-over-year, from $95.28B to $94.8B.

What is the long-term trend for AbbVie's indefinite- lived intangible impairment?

Over 5 years (2020 to 2025), AbbVie's indefinite- lived intangible impairment has grown at a -0.5% compound annual growth rate (CAGR), from $97.41B to $94.87B.

AbbVie ABBV Indefinite- lived intangible impairment

Indefinite- lived intangible impairment at other companies

PfizerPFE

——

Cardinal HealthCAH

——

Vertex PharmaceuticalsVRTX

——

Bausch Health CompaniesBHC

——

Establishment LabsESTA

——

Bausch + LombBLCO

——

Other financials

Income statement

See full

Revenue$15.0B+12.4%

Gross profit$10.8B+15.4%

Operating income$4.0B+6.9%

Net income$695.0M-46.0%

EPS (diluted)$0.39-45.8%

Balance sheet

See full

Cash & equivalents$9.4B+81.5%

Total debt$62.4B+1.8%

Total equity-$6.7B-569%

Total assets$136.46B+0.2%

Cash flow

See full

Operating cash flow$3.8B+134%

CapEx$265.0M+12.8%

Free cash flow$3.6B+155%

Valuation

See full

Market cap$444.6B+39.8%

P/E122.3×+37.8×

P/S7.1×+1.6×

Profitability

See full

Gross margin70.7%0.0pp

Operating margin24.4%—

Net margin5.8%-1.5pp

FCF margin31.8%+5.0pp

Returns & leverage

See full

Return on equity89%+32.7pp

Debt / equity46.6×+38.6×

Current ratio0.8×0.0×

Where this comes from

Reported directly by AbbVie in its filing.

Tagged under the XBRL concept us-gaap:IntangibleAssetsGrossExcludingGoodwill.

The official record: AbbVie’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about AbbVie's indefinite- lived intangible impairment.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is AbbVie's indefinite- lived intangible impairment?: AbbVie (ABBV) reported indefinite- lived intangible impairment of $94.8B in Q1 2026.
How has AbbVie's indefinite- lived intangible impairment changed year-over-year?: AbbVie's indefinite- lived intangible impairment decreased by 0.5% year-over-year, from $95.28B to $94.8B.
What is the long-term trend for AbbVie's indefinite- lived intangible impairment?: Over 5 years (2020 to 2025), AbbVie's indefinite- lived intangible impairment has grown at a -0.5% compound annual growth rate (CAGR), from $97.41B to $94.87B.